Equities analysts expect that Davita Inc (NYSE:DVA) will report earnings per share of $0.90 for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Davita’s earnings, with the lowest EPS estimate coming in at $0.80 and the highest estimate coming in at $0.93. Davita posted earnings of $0.81 per share during the same quarter last year, which would indicate a positive year over year growth rate of 11.1%. The business is expected to announce its next quarterly earnings results on Tuesday, November 6th.
According to Zacks, analysts expect that Davita will report full year earnings of $4.02 per share for the current fiscal year, with EPS estimates ranging from $3.97 to $4.04. For the next year, analysts forecast that the business will post earnings of $5.16 per share, with EPS estimates ranging from $4.65 to $6.16. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow Davita.
Davita (NYSE:DVA) last announced its quarterly earnings data on Wednesday, August 1st. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.97 by $0.08. The company had revenue of $2.89 billion for the quarter, compared to analysts’ expectations of $2.88 billion. Davita had a net margin of 4.30% and a return on equity of 14.49%. The business’s revenue was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.92 EPS.
Several research firms have recently weighed in on DVA. Zacks Investment Research raised shares of Davita from a “sell” rating to a “hold” rating in a research report on Tuesday, August 7th. JPMorgan Chase & Co. raised shares of Davita from an “underweight” rating to a “neutral” rating in a research report on Thursday. Finally, William Blair reissued a “buy” rating on shares of Davita in a research report on Wednesday, June 6th. Five equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $82.13.
Shares of Davita stock traded down $0.55 during trading on Friday, hitting $70.78. The stock had a trading volume of 1,158,552 shares, compared to its average volume of 1,500,578. The company has a market cap of $11.28 billion, a P/E ratio of 21.32, a price-to-earnings-growth ratio of 1.01 and a beta of 1.10. The company has a debt-to-equity ratio of 1.82, a current ratio of 1.90 and a quick ratio of 1.88. Davita has a 1 year low of $52.51 and a 1 year high of $80.71.
Institutional investors have recently added to or reduced their stakes in the company. Alps Advisors Inc. boosted its holdings in shares of Davita by 11.1% during the second quarter. Alps Advisors Inc. now owns 10,781 shares of the company’s stock worth $749,000 after purchasing an additional 1,080 shares during the period. OppenheimerFunds Inc. boosted its holdings in shares of Davita by 58.7% during the second quarter. OppenheimerFunds Inc. now owns 4,066,317 shares of the company’s stock worth $282,365,000 after purchasing an additional 1,504,347 shares during the period. Tibra Equities Europe Ltd acquired a new stake in shares of Davita during the second quarter worth approximately $1,627,000. Oppenheimer Asset Management Inc. acquired a new stake in shares of Davita during the second quarter worth approximately $3,421,000. Finally, Janus Henderson Group PLC boosted its holdings in shares of Davita by 3.0% during the second quarter. Janus Henderson Group PLC now owns 1,284,092 shares of the company’s stock worth $89,168,000 after purchasing an additional 37,362 shares during the period. 87.80% of the stock is currently owned by institutional investors and hedge funds.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Article: Hedge Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.